Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
2008 1
2011 2
2013 1
2014 1
2015 1
2016 2
2017 3
2020 1
2021 1
2022 3
2023 5
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
Farina A, Villagrán-García M, Fourier A, Pinto AL, Chorfa F, Timestit N, Alberto T, Aupy J, Benaiteau M, Birzu C, Campetella L, Cotton F, Dalle S, Delaruelle CF, Dumez P, Germi R, Le Maréchal M, Maillet D, Marignier R, Pegat A, Psimaras D, Rafiq M, Picard G, Desestret V, Quadrio I, Honnorat J, Joubert B. Farina A, et al. Among authors: alberto t. Lancet Reg Health Eur. 2024 Jul 25;44:101011. doi: 10.1016/j.lanepe.2024.101011. eCollection 2024 Sep. Lancet Reg Health Eur. 2024. PMID: 39170102 Free PMC article.
Brain atrophy patterns in anti-IgLON5 disease.
Yogeshwar SM, Bartels F, Grüter T, Muñiz-Castrillo S, Picard G, Crijnen YS, Bernard E, Heidbreder A, Zekeridou A, Ringelstein M, Kraft A, Kovac S, Wandinger KP, de Vries JM, Boon AJW, Veenbergen S, Geis C, Penner L, Melzer N, Leypoldt F, Blaabjerg M, Pittock SJ, Gaig C, Sabater L, Santamaria J, Graus F, Dalmau J, Prüss H, Höftberger R, Schreiner B, McKeon A, Lewerenz J, Irani S, Mignot E, Titulaer MJ, Ayzenberg I, Honnorat J, Finke C; IgLON5 Imaging Consortium. Yogeshwar SM, et al. Brain. 2025 Jul 12:awaf256. doi: 10.1093/brain/awaf256. Online ahead of print. Brain. 2025. PMID: 40650880
Global treatment of haemorrhoids-A worldwide snapshot audit conducted by the International Society of University Colon and Rectal Surgeons.
Samalavicius NE, Gupta RK, Nunoo-Mensah J, Fortunato R, Lohsiriwat V, Khanal B, Kumar A, Sah B, Cerkauskaite D, Dulskas A; 2023 International Society of Universities of Colon and Rectal Surgeons (ISUCRS) Collaborating Group. Samalavicius NE, et al. Colorectal Dis. 2024 Oct;26(10):1797-1804. doi: 10.1111/codi.17140. Epub 2024 Aug 21. Colorectal Dis. 2024. PMID: 39169548
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.
Villagrán-García M, Farina A, Muñiz-Castrillo S, Wucher V, Dhairi M, Timestit N, Ciano-Petersen NL, Vogrig A, Picard G, Benaiteau M, Psimaras D, Petrova AV, Alberto T, Aupy J, Giry M, Rogemond V, Desestret V, Joubert B, Honnorat J. Villagrán-García M, et al. Among authors: alberto t. Brain Commun. 2023 Sep 21;5(5):fcad247. doi: 10.1093/braincomms/fcad247. eCollection 2023. Brain Commun. 2023. PMID: 37794924 Free PMC article.
Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis.
Rigollet C, Freeman SA, Perriguey M, Stellmann JP, Graille-Avy L, Lafontaine JC, Lemarchant B, Alberto T, Demortière S, Boutiere C, Rico A, Hilézian F, Durozard P, Pelletier J, Maarouf A, Zéphir H, Audoin B. Rigollet C, et al. Among authors: alberto t. Neurotherapeutics. 2025 Apr;22(3):e00554. doi: 10.1016/j.neurot.2025.e00554. Epub 2025 Feb 20. Neurotherapeutics. 2025. PMID: 39979176 Free PMC article.
25 results